Micregen’s Board of Directors is composed of highly accomplished individuals with extensive and diverse experience in various fields related to business building, biotech science, and management. They bring a wealth of knowledge and expertise to the table, acquired over many years of working in academia, private and public companies. The Board member’s experience includes leading successful business ventures, working with groundbreaking regenerative biotech research and understanding the intricacies of managing complex organisations.
The Board’s collective experience and professional networks allow them to provide invaluable guidance and leadership to the company, ensuring that Micregen is well-positioned to navigate the challenges and capitalise on the opportunities in today’s rapidly changing business landscape.
Barry Sharples
Executive Chairman
Over the last 35 years, Barry has founded and managed several technology companies through to sale and IPO.
In 2012 he was treated as a patient at one of the founding scientist's clinics and subsequently began establishing the strategy to take this extraordinary regenerative technology to a global market before formally founding Micregen together in 2015.
Athan Papadopoulos MD
Managing Director
A medical doctor who specialised in Biopathology. Over 20 years global biopharmaceutical experience, at a CRO, Novartis, Sanofi and Emergex. Holding international roles as Vice President and Chief Medical Officer.
Athan has headed clinical research and overseen development programs in biologics and immunotherapies. He led development of several important medicines until licensure, and initiated programs that advance the science that is the foundation of medicine.
Steve Ray, PhD
Chief Scientist
Former Senior Lecturer in Acute & Emergency Care at Oxford Brookes University, Professor of Neuroscience at the Carrick Institute Florida, served as International Scientific Advisor to major South African and Swiss stem cell clinics and cell banks.
Steve has extensive experience in the clinical application of stem cell secretomes that extends over twenty-five years. He has presented over one hundred papers at international scientific conferences, with nineteen as the keynote speaker. He has already translated his research through to proven clinical practice.